207 related articles for article (PubMed ID: 27908678)
1. Avoidance of late rectal toxicity after high-dose-rate brachytherapy boost treatment for prostate cancer.
Kragelj B; Zlatic J; Zaletel-Kragelj L
Brachytherapy; 2017; 16(1):193-200. PubMed ID: 27908678
[TBL] [Abstract][Full Text] [Related]
2. High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity.
Chicas-Sett R; Farga D; Perez-Calatayud MJ; Celada F; Roldan S; Fornes-Ferrer V; Ibanez-Rosello B; Tormo A; Benlloch JM; Perez-Calatayud J
Brachytherapy; 2017; 16(3):511-517. PubMed ID: 28366276
[TBL] [Abstract][Full Text] [Related]
3. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
Nitsche M; Brannath W; Brückner M; Wagner D; Kaltenborn A; Temme N; Hermann RM
Br J Radiol; 2017 Feb; 90(1070):20160370. PubMed ID: 27936891
[TBL] [Abstract][Full Text] [Related]
5. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
6. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors.
Wachter S; Gerstner N; Goldner G; Pötzi R; Wambersie A; Pötter R
Radiother Oncol; 2001 Apr; 59(1):65-70. PubMed ID: 11295208
[TBL] [Abstract][Full Text] [Related]
7. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.
Moulton CR; House MJ; Lye V; Tang CI; Krawiec M; Joseph DJ; Denham JW; Ebert MA
Radiat Oncol; 2016 Oct; 11(1):144. PubMed ID: 27799048
[TBL] [Abstract][Full Text] [Related]
8. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
9. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579
[TBL] [Abstract][Full Text] [Related]
10. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study.
Fiorino C; Fellin G; Rancati T; Vavassori V; Bianchi C; Borca VC; Girelli G; Mapelli M; Menegotti L; Nava S; Valdagni R
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1130-7. PubMed ID: 17881142
[TBL] [Abstract][Full Text] [Related]
11. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
[TBL] [Abstract][Full Text] [Related]
12. Learning curve of MRI-based planning for high-dose-rate brachytherapy for prostate cancer.
Buus S; Rylander S; Hokland S; Søndergaard CS; Pedersen EM; Tanderup K; Bentzen L
Brachytherapy; 2016; 15(4):426-434. PubMed ID: 27220699
[TBL] [Abstract][Full Text] [Related]
13. The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer.
Defraene G; Van den Bergh L; Al-Mamgani A; Haustermans K; Heemsbergen W; Van den Heuvel F; Lebesque JV
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1233-42. PubMed ID: 21664059
[TBL] [Abstract][Full Text] [Related]
14. Toxicities and dose-volume histogram parameters of MRI-based brachytherapy for cervical cancer.
Kim Y; Kim YJ; Kim JY; Lim YK; Jeong C; Jeong J; Kim M; Lim MC; Seo SS; Park SY
Brachytherapy; 2017; 16(1):116-125. PubMed ID: 27876378
[TBL] [Abstract][Full Text] [Related]
15. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy).
Cozzarini C; Fiorino C; Ceresoli GL; Cattaneo GM; Bolognesi A; Calandrino R; Villa E
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):688-94. PubMed ID: 12573756
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
[TBL] [Abstract][Full Text] [Related]
17. Rectal dose constraints for salvage iodine-125 prostate brachytherapy.
Peters M; Hoekstra CJ; van der Voort van Zyp JR; Westendorp H; van de Pol SM; Moerland MA; Maenhout M; Kattevilder R; van Vulpen M
Brachytherapy; 2016; 15(1):85-93. PubMed ID: 26614233
[TBL] [Abstract][Full Text] [Related]
18. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
[TBL] [Abstract][Full Text] [Related]
19. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
20. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.
Skwarchuk MW; Jackson A; Zelefsky MJ; Venkatraman ES; Cowen DM; Levegrün S; Burman CM; Fuks Z; Leibel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):103-13. PubMed ID: 10758311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
